Rhythm Pharmaceuticals, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2019 Annual Meeting of Stockholders held on June 19, 2019. Rhythm Pharmaceuticals, Inc. is an emerging growth company incorporated in Delaware, with its principal executive offices in Boston, MA. Its common stock trades on the Nasdaq Global Market under the symbol RYTM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Election of Directors (Class II): Three nominees were elected to serve until the 2022 Annual Meeting.
- Jennifer Good: 28,033,908 votes for; 4,538 votes withheld; 36,100 abstaining; 2,720,748 broker non-votes.
- Todd Foley: 24,084,965 votes for; 19,553 votes withheld; 3,970,028 abstaining; 2,720,748 broker non-votes.
- Ed Mathers: 21,664,321 votes for; 2,177,752 votes withheld; 4,232,473 abstaining; 2,720,748 broker non-votes.
- Ratification of Independent Auditor: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019, was ratified.
- Votes For: 30,764,774
- Votes Against: 1,375
- Votes Abstaining: 29,145
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class II directors (Jennifer Good, Todd Foley, Ed Mathers) extending to the 2022 Annual Meeting.
- Confirm the ratification of Ernst & Young LLP as the auditor for the fiscal year ending December 31, 2019.
- Note the significant number of broker non-votes (2,720,748) recorded for the director elections.
- Review the high number of abstentions and votes withheld for nominees Todd Foley and Ed Mathers compared to Jennifer Good.